Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)

NCT01316185 is registered in ClinicalTrials.gov with Eiger BioPharmaceuticals as lead sponsor.

NCT NCT01316185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01316185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)
Lead sponsor
Eiger BioPharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2011
Completion date
April 30, 2013
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis d